Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Affiliations
1Department of Obstetrics and Gynecology, Division of Vaccine Research, The Ohio State Wexner Medical Center, Columbus, OH, USA.
2Department of Obstetrics and Gynecology, Division of Vaccine Research, The Ohio State Wexner Medical Center, Columbus, OH, USA. Pravin.kaumaya@osumc.edu.
3Arthur G. James Cancer Hospital & Solove Research, Comprehensive Cancer Center, Columbus, OH, USA. Pravin.kaumaya@osumc.edu.
PMID: 33772155 DOI: 10.1038/s41416-021-01342-9
Abstract
We developed a PD-1 B-cell epitope vaccine (PD1-Vaxx) to rival nivolumab therapy which has received ethics approvals for a Phase 1 clinical trial in Australia. The US FDA granted Investigational New Drug approval to Imugene Ltd for clinical testing in NSCLC. We demonstrated synergistic vaccine combinations with an HER-2 targeted vaccine (B-Vaxx).
https://pubmed.ncbi.nlm.nih.gov/33772155/
https://clinicaltrials.gov/ct2/show/NCT04432207
Other news to note for Sept. 23, 2020 | 2020-09-23 | BioWorld
www.bioworld.com › articles › 498101-other-news-to
Sep 23, 2020 · Mymetics Corp., of Epalinges, Switzerland, produced virosome formulations which incorporate the SARS-CoV-2 recombinant protein. The virosomes will be tested by Baylor College of Medicine with preclinical data expected in three months.
Where is the data on this MR.KEMPERS. 7months gone by now!!
OXFORD, UK – 5 May 2021 – Enesi Pharma (“Enesi”), an innovative biotechnology company developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies, announces it has achieved a key milestone in its project to develop needle-free thermostable unit solid-dose live vaccines with retained activity against Measles and Rubella. The project, which started in October 2019, received funding from the Bill & Melinda Gates Foundation.
LOOKS LIKE YOU GOT BEATEN OUT AGAIN MR. KEMPER'S AND MYMETICS!!
https://www.enesipharma.com/enesi-pharma-achieves-key-milestone-in-development-of-thermostable-solid-dose-live-vaccines-against-measles-and-rubella/
Upperton Pharma Solutions - D2N2 UpScaler Case Study
23 April 2021
While the Upperton team possess a huge amount of scientific knowledge and technical skill, it needed support to help it get the right business and management structures in place to continue its growth trajectory and exploit new markets and opportunities. Dr Laura Mason, Upperton’s director of business operations, attended several UpScaler workshops, including performance management, HR, and finance, to expand her knowledge of these key areas. The workshops have enabled Dr Mason and her team to implement a number of changes within the business, including putting in place a structure for staff performance reviews, and other team-building initiatives.
https://www.d2n2growthhub.co.uk/about/case-studies/upperton-pharma-solutions-d2n2-upscaler-case-study/
At lease Laura Mason has it right. Management Structure / Mr. Kemper's can sure use that as well as growth trajectory and exploit new markets and opportunities. And giving news to the public of were the company is and where it's headed. KEEPING THE PUBLIC INFORMED ON THE COMPANY!!
Your search results of Mymetics
Found 1 results. Showing 1 of 1
ARTICLE
FORMULATION OPTIONS IN NASAL DRUG DELIVERY
Date: 17th May 2021
Author: Richard Johnson
Topics: EXPERT VIEW, NASAL, RESPIRATORY
Companies: Upperton Pharma Solutions
Richard Johnson discusses the advantages of nasal delivery and why there is growing interest in this route of administration, as well as considering some of the challenges that may arise during the development of nasal formulations for use in the clinic, and the regulatory and testing requirements associated with them.
https://www.ondrugdelivery.com/?s=mymetics
CpG 1018
CpG 1018 is a recently developed adjuvant used in Heplisav-B vaccine. It is made up of cytosine phosphoguanine (CpG) motifs, which is a synthetic form of DNA that mimics bacterial and viral genetic material. When CpG 1018is included in a vaccine, it increases the body’s immune response.
In pre-licensure clinical trials, adverse events after Heplisav-B were comparable to those observed after another U.S.-licensed, non-adjuvanted hepatitis B vaccine.
https://www.cdc.gov/vaccinesafety/concerns/adjuvants.html
https://pubmed.ncbi.nlm.nih.gov/25344321/
Vaccine adjuvants: Understanding the ... - ScienceDirect
www.sciencedirect.com › science › article
May 27, 2019 · Among these, CpG-B class, e.g., CpG 1018, 1826, 2007, is the most commonly used one in pre-clinical and clinical trials . HEPLISAV-B, a hepatitis B vaccine approved by the FDA in 2017, is the first vaccine adjuvanted with CpG ODN 1018 .
https://www.researchgate.net/publication/338945184_Vaccination_with_virosomally_formulated_recombinant_CyRPA_elicits_protective_antibodies_against_Plasmodium_falciparum_parasites_in_preclinical_in_vitro_and_in_vivo_models
NOTIFICATION OF LATE FILING
https://www.sec.gov/Archives/edgar/data/927761/000165495421005935/mymx_nt10q.htm
Vaccines, Virosome
vaccines using virosomes as the antigen delivery system that stimulates the desired immune response.
https://lookfordiagnosis.com/mesh_info.php?term=Vaccines%2C+Virosome&lang=1
Thank-You for that my Friend, That means alot!! :)
To your Rogier Sanders on Trimers.
https://humanvaccine.duke.edu/dhvi-special-virtual-event-rogier-sanders-phd
Gp41 antigens - Mymetics Corporation
www.freepatentsonline.com › 8765137
According to the present invention, a polypeptide allows the formation of gp41-trimers and has retained the native gp41 antigenicity and presents a minimal IL-2 cross reactivity. Such cross reactivity can be determined by methods well known to the skilled man in the art such as gp41-ELISA and gp41-dot blot.
https://www.freepatentsonline.com/8765137.html
I myself would like to hear from Dr. Thomas Staehelin himself. 5 min with him we would know MYMX plans. Right now I really do not have any faith in a ly*** CEO that leads investors the wrong way. He's going to hear from all of us in the near future!! That I guarantee!! Prove it other wise CEO!!
I do not get this MANAGEMENT either! But what I do know is the dd's here are pretty much spot on!! :)
Since February 1, 2021, Anergis SA has moved into liquidation as it was not able to raise sufficient funds to continue.
So Mr. K what are you going to do with this great Asset? Are you going to let it sit there? Why don't you get off your high horse and try and bring this to market. We all know that Amy Wyss was in on investment with Anergis SA. Do some calls you and Dr. S to the big goose H. Wyss. and get this going. I'm sure that the Offshore investors here could also fund the trials. Just Saying! Do something with this asset! Along with HIV, Catalent could support all the trials on HIV and bring it to market! Get Busy!!
JUST SAYING!!
In 2012 a start-up company called Biolife Science had been incorporated to develop this immunotherapy. Early-stage funding was secured from Australian and US investors in 2013, after which Biolife was taken public in December 2013 in a reverse takeover of an Australian drug development company called Imugene, whose name was retained after the merger. Around US$8m was spent on the HER-Vaxx programme prior to its becoming the 'new Imugene'.
Positive Phase I Trial Results for Pevion Biotech Ltd.'s and Bio Life Science's Breast Cancer Vaccine | BioSpace
... s and Bio Life Sciences Breast Cancer Vaccine - read this article along with other careers information, tips and advice on ... For its vaccine development, the company uses its virosome-based technology which is already validated by two registered and ... The vaccine was generally well tolerated and no vaccine-related serious or severe adverse effects were reported. The vaccine ... The trivalent vaccine was found to be safe, well tolerated and immunogenic in patients moderately over-expressing the HER-2/neu ...
https://www.biospace.com/article/releases/positive-phase-i-trial-results-for-pevion-biotech-ltd-s-and-b-bio-life-science-b-s-breast-cancer-vaccine-/
innate Biopharma, an oncology biotech developing small molecule kinase inhibitors, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
(PDF) Peripherally Administered Nanoparticles Target ...
www.researchgate.net › publication › 236461466
Apr 23, 2013 · Toon Stegmann is employed by Mymetics BV. ... using a phosphatidylinositol 3-kinase inhibitor of macropinocytosis ... taken up by bone marrow cells as a function of the PI3K inhibitor (Ly294002 ...
https://www.researchgate.net/publication/236461466_Peripherally_Administered_Nanoparticles_Target_Monocytic_Myeloid_Cells_Secondary_Lymphoid_Organs_and_Tumors_in_Mice
(PDF) Fusion of human neutrophil phagosomes with lysosomes in ...
www.researchgate.net › publication › 11878031_Fusion
selective tyrosine kinase inhibitors (33) suggest the involvement. of tyrosine phosphorylation in intact human neutrophils. In ad- ... Pascale Peyron, Isabelle Maridonneau-Parini and Toon Stegmann.
https://www.researchgate.net/publication/11878031_Fusion_of_human_neutrophil_phagosomes_with_lysosomes_in_vitro_Involvement_of_tyrosine_kinases_of_the_Src_family_and_inhibition_by_mycobacteria
(PDF) Metabolic fate of plasma membrane diacylglycerols in ...
www.researchgate.net › publication › 21520255
Toon Stegmann. Mymetics SA; ... kinase inhibitor . R . 59022 . and the lipase inhibitor . RG . 80267 . on the metabolism . of ["CJDOG . Radioactivity recovered in different cellular lipids from ..
Metabolic Fate of Plasma Membrane Diacylglycerols in NIH 3T3 Fibroblasts*
https://www.researchgate.net/publication/21520255_Metabolic_fate_of_plasma_membrane_diacylglycerols_in_NIH_3T3_fibroblasts
Fibroblast Growth Factor basic Protein, Human recombinant - Merck
www.merckmillipore.com › INTL › en
Fibroblast Growth Factor basic Protein, Human recombinant The Fibroblast Growth Factor-basic (FGF-b) is a heparin binding growth factor which stimulates the proliferation of a wide variety of cells including mesenchymal, neuroectodermal & endothelial cells.
Merck and Baylor Medical School work together to advance the new coronary pneumonia vaccine manufacturing platform
Credit Associated Press Source: At the Associated Press 2527 0A + A -
2020
05/28
share
Read: Leading technology company Merck and Baylor College of Medicine in Houston, Texas, usa today announced further expansion of their ongoing partnership to advance the new coronary pneumonia vaccine manufacturing platform, with the aim of accelerating access to Phase I clinical trials
Merck, a leading technology company, and Baylor College of Medicine in Houston, Texas, today announced further expansion of their ongoing partnership to advance the new coronary pneumonia vaccine manufacturing platform, which aims to accelerate progress to Phase I clinical trials.
Udit Batra, a member of Merck's executive committee and chief executive of the life sciences division, said: "Vaccine manufacturing is extremely complex, so we are working together to develop a process to accelerate the manufacture of a candidate vaccine for Baylor's new coronary pneumonia. To fight this pandemic, we need to produce an unprecedented number of vaccines in a very short period of time, and we need as many methods as possible to succeed. ”
Because of the complexity and diversity of vaccine manufacturing methods, there are no standard manufacturing templates or processes, which makes vaccine production a challenge for every organization to compete for a safe and effective new coronary pneumonia vaccine. Merck worked with researchers at Baylor Medical School and texas Children's Hospital Vaccine Development Center to use their key experience with ongoing schistosomiasis vaccine collaborations to optimize production processes and advance the production of two new coronary pneumonia candidates, including the CoVRBD219-N1 candidate vaccine, which is expected to enter clinical trials later this year. Merck will help accelerate the sustainability of its large-scale manufacturing. The partnership will focus on increasing productivity, productivity, extensiveness, scalability and cost-effectiveness.
Dr. Peter Hotez and Dr. Maria Elena Bottazzi, dean of the National School of Tropical Medicine at Baylor School of Medicine and co-director of the Texas Children's Hospital Vaccine Development Center, said, " Our initial collaboration with Merck provides a very important and critical framework for our rapid validation and preparation of the production of neglected tropical disease vaccines for global use. ”
"Expanding our collaboration, including on pandemic diseases, will now enable us to accelerate the development of scalable and affordable new coronary pneumonia candidate vaccine manufacturing processes and enable them to accelerate vaccine production in low- and middle-income countries as quickly as possible," said Botaz, who heads product development activities and is vice president of baylor's National School of Tropical Medicine. ”
The Merck-Baylor team will improve the CoVRBD219-N1 vaccine candidate vaccine manufacturing platform, originally developed from 2011 to 2016, with the goal of treating SARS. In addition, they will develop a manufacturing platform for a second candidate vaccine for coronary pneumonia, reducing the time to phase 1 clinical trials. The goal of this collaboration is to develop appropriate manufacturing processes and procedures to create a scale-up approach for commissioning and subsequent industrial production.
Merck process development scientists and biomanufactive engineers, as well as researchers at the Texas Children's Hospital Vaccine Development Center, will enter into a partnership for the first time in 2018 to advance vaccine development and production and strengthen responses to outbreaks such as new corona pneumonia. By working through existing process development platforms to lay the initial foundation, teams can quickly reduce the time it takes for vaccines to enter a clinic and achieve a key goal.
All Merck press releases are sent by e-mail at the same time as they are posted on Merck's website. Please visit the www.merckgroup.com/subscribe, register online, change options or stop the service.
Baylor Medical School and Texas Children's Hospital Vaccine Development Center received FUNDing from NAID for early development of the CoVRBD219-N1 candidate vaccine, as well as the recent preliminary development of a second new coronary pneumonia candidate vaccine. In addition, Baylor and texas Children's Hospital Vaccine Development Center hope to promote the development of new coronary pneumonia candidate vaccine through alliances with PATH to support the use of vaccines in low- and middle-income countries.
About Merck
Merck is a leading technology company focused on three areas: healthcare, life sciences and high-performance materials. Approximately 57,000 employees worldwide serve Merck and are committed to creating sustainable, enjoyable lifestyles that improve the daily lives of millions of people. From advancing gene editing technology and discovering unique ways to treat the toughest diseases, to supporting smart devices, Merck is everywhere. In 2019, Merck's sales in 66 countries were EUR 16.2 billion.
Scientific exploration and responsible management are key to Merck's technological progress. This is why Merck has evolved since its founding in 1668. The founding family still holds a majority stake in publicly traded companies. Merck owns the name and brand worldwide, with the exception of the United States and Canada, where merck uses EMDSerono to run healthcare, Millipore Sigma to run its life sciences business, and EMDPerformance Materials to run its high-performance materials business.
Merck and Baylor Medical School are working together to advance the new coronary pneumonia vaccine manufacturing platform
https://news.yaozh.com/archive/30126.html
HAD TO TRANSLATE IT!! :)
Nice Find My Friend!! :)
MERCK 2020 Q4 REPORT
Our Response to Covid-19*
Page 20
In addition, we are tapping into our existing collaborations to support projects that target Covid-19 vaccine and
therapy development. As part of our collaborations with Oxford University in the United Kingdom and Baylor
College of Medicine in Houston, Texas, USA, we supported the process development, manufacturing, and scale
up of their respective Covid-19 vaccines candidates.
Page 60
We also announced an extension of our ongoing collaboration with Baylor College of Medicine in Houston,
Texas, USA, which previously focused on vaccine development for tropical disease outbreaks, to now advance a
vaccine manufacturing platform for Covid-19. Our joint work supports the accelerated transition to Phase I
clinical trials, optimizing the production process to advance two Covid-19 vaccine candidates, including the CoV
RBD219-N1 vaccine candidate originally developed to target SARS.
https://www.emdgroup.com/investors/reports-and-financials/earnings-materials/2020-q4/us/2020-Q4-Report-NA.pdf
Typical Lyi** CEO! Prove other wise Dr. Kemper's !! Do you run this company and have a say or are you just a puppet at the hands of the Offshore moron's.
WH Cancelled stack bids below, That's why it went down! MM Took Advantage
He held it up all this time for all and company!! company needs to help here with great PR'S NOW
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=163755469
I'm not happy with Dr. Kempers!!
Acknowledgments
We are grateful to Dr. Vincent Munster (NIAID) for providing the spike expression plasmid for SARS-CoV-2.
SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice
https://www.tandfonline.com/eprint/N5QHNDE3ZBSF5AEWPDGV/full?target=10.1080/21645515.2021.1901545
https://irp.nih.gov/pi/vincent-munster
Vincent Jacobus Munster
Dr. Vincent Munster received his Ph.D. in virology from Erasmus University, Rotterdam, the Netherlands, in 2006. During his Ph.D. studies, Dr. Munster studied the ecology, evolution, and pathogenesis of avian influenza viruses. He continued his training at the Erasmus Medical Center from 2006 to 2009, where he worked within the Center for Research on Influenza Pathogenesis and Surveillance (CRIPS) focusing on pathogenicity and human-to-human transmission of influenza A viruses. Dr. Munster joined NIAID’s Laboratory of Virology as a visiting fellow in 2009 to study the ecology of filoviruses and henipaviruses. In 2013, Dr. Munster established the Virus Ecology Unit and worked as an independent tenure-track investigator. The mission of the Virus Ecology Unit is to elucidate the ecology of emerging viruses and drivers of zoonotic and cross-species transmission. The main objectives of his research program aim to identify the underlying biotic or abiotic changes in virus-host ecology that allow these emerging viral pathogens to cross the species barrier.
Lab Information
NIAID/DIR
https://www.molecularcloud.org/s/vincent-jacobus-munster
Nosocomial Transmission of Emerging Viruses via Aerosol-Generating Medical Procedures
by Seth D. Judson 1,2OrcID andVincent J. Munster 2,*OrcID
1
Department of Medicine, University of Washington, Seattle, WA 98195, USA
2
Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA
https://www.mdpi.com/1999-4915/11/10/940/htm
Vincent Munster
Chief Virus Ecology Unit at National Institutes of Health
Scientists at Rocky Mountain Labs honored for Coronavirus research
JANUARY 13, 2021 BY MICHAEL HOWELL
https://bitterrootstar.com/2021/01/scientists-at-rocky-mountain-labs-honored-for-coronavirus-research/
Interesting
https://www.c4dt.org/partners/
Jennifer Bachmann
Academy
https://www.c4dt.org/team/
https://www.linkedin.com/in/jennifer-bachmann-ona-996273121/detail/recent-activity/
Jennifer Bachmann Ona likes this
Center for Digital Trust (C4DT), EPFL
Center for Digital Trust (C4DT), EPFL
272 followers
1mo • 1 month ago
Follow
Take a look at Balthasar Staehelin, Director of Digital Transformation and Data at International Committee of the Red Cross - ICRC's
recommendation of our "Foundations of ICT for Decision Makers" course. This 5-day course will be held from the 7th-11th of June 2021 on the EPFL campus and is reserved for the C4DT community. For more information on how to register, contact jennifer.bachmann-ona@epfl.ch.
#course #digitaltransformation #fict #machinelearning #blockhain #cybersecurity #dataprivacy #digitaltrust
Hmmm Nice Address
VFI Lausanne laboratories
Route de la Corniche 5
1066 Epalinges
Switzerland
https://www.vaccineformulationinstitute.org/news/swe/
Big Time in peptides!! used with virosomes alot with other companies!! :)
Imugene (ASX:IMU) reports clinical milestone for HER-Vaxx ...
themarketherald.com.au › imugene-asximu-reports
Apr 21, 2021 · Imugene (IMU) has achieved a clinical milestone for progression-free survival (PFS) in its phase two gastric cancer clinical trial. The study is assessing whether the company's HER-Vaxx immunotherapy can improve, firstly, overall survival and, secondly, progression-free survival.
https://themarketherald.com.au/imugene-asximu-reports-clinical-milestone-for-her-vaxx-2021-04-21/
Nice when there using VIROSOMES
Morning MYMX!! Let's see if Mr. K puts out the Q today?
Mymetics Corporation
Overview
May 2021
Overview - mymetics.com
www.mymetics.com › files › 8116/2081/0445
Virosomes were able to fully reverse asthma symptoms and lung inflammation in a sublingual therapeutic model of birch pollen allergy (1) (1) Journal Clinical & Experimental Allergy, January 2021: Bet v 1 contiguous overlapping peptides anchored to virosomes with TLR4 agonist enhance immunotherapy efficacy in mice.
https://www.mymetics.com/files/8116/2081/0445/May21-Mymetics_Overview.pdf
This or this???
This??
https://cdn.unitycms.io/image/ocroped/1200,1200,1000,1000,0,0/ylG5i5O-yGI/2OhajEP64pTB0bkmg8JNnt.jpg
OR THIS??
https://assets.letemps.ch/sites/default/files/styles/article_detail_mobile/public/media/2013/06/14/178a5c60-d51a-11e2-a409-316582df7416.jpg?itok=pKTpzs1m
https://www.tradingsat.com/media/pictures/realsize/news/stallergenes-greer-136971.jpg
https://blueocean-ventures.com/wp-content/uploads/2016/11/logo_anergis-uai-258x161.png
interesting!!
Wyss and Bertarelli
https://assets.letemps.ch/sites/default/files/media/2016/11/03/file6nj5yezjrfsfmsg4aw1.jpg
https://img.nzz.ch/C=W815,H458,X0,Y274/O=75/http://s3-eu-west-1.amazonaws.com/nzz-img/2013/06/14/1.18099397.1371237426.jpg?width=400&height=224&fit=bounds&quality=75&auto=webp&crop=815,458,x0,y274
Wonder if it's going to be telling on anything that will push the volume through the roof!! :) You must like Star Wars!! Gave you a mark!! you have 2 now
PROGRESS AND PLANS OF NATIONAL NANOTECHNOLOGY INITIATIVE (NNI ...
www.nano.gov › sites › default
peptides was funded to manufacture new virosome vaccine candidates in a form that can be delivered through a nasal spray. Other ongoing activities and plans for 2019–2020 focus on building an armamentarium of particulated
https://www.nano.gov/sites/default/files/NIH-2019-NNI-progress-plans-final.pdf
SEC
www.sec.gov › Archives › edgar
“HER2/neu positive Cancer Product” means the combination of influenza virosomes with HER-2 neutralizing antigens resulting in a virosome based Vaccine for HER2/neu positive Cancer. 1.17 “ ICH Guidelines ” means the guidelines of the “International Conference on Harmonisation of Technical Requirements for Registration of ...
https://www.sec.gov/Archives/edgar/data/927761/000114036114028531/ex10_1.htm
University of Groningen Immunotherapy based on influenza ...
research.rug.nl › files › 2794291
Download date: 11-04-2021. ... virosomes and recombinant Semliki Forest virus ... Dutch Cancer Society, Amsterdam, The Netherlands
https://pure.rug.nl/ws/portalfiles/portal/2794291/14_thesis.pdf
Let's see if this goes down!!
Another thing if you have a cure for Asthma Mr. K why not FAST TRACK and help the people out there!! GET IT DONE!!
Thanks Siar!!